Eyegate Pharmaceuticals Inc., of Waltham, Mass., said it entered a definitive agreement with a single health care institutional investor to purchase shares of common stock and shares of series A convertible preferred stock for gross proceeds of approximately $3.77 million. In a registered direct offering it will sell 441,000 shares of common stock at $2.25 per share and 2,776.5 shares of series A convertible preferred stock, at $1,000 per share. Eyegate intends to use the net proceeds to obtain additional capital to support its operations, including for clinical trials, for working capital and for other general corporate purposes, which will include the pursuit of other research and development efforts and could also include the acquisition or in-license of other products, product candidates or technologies.
Global Blood Therapeutics Inc., of South San Francisco, said it closed its underwritten public offering of 6.4 million shares of common stock at $18.75 per share. The net proceeds will be approximately $112.3 million.
Noxopharm Ltd., of Sydney, said is seeking to raise A$6 million (US$4.4 million) in an IPO and to list on the ASX. In its offering 30 million shares will be sold at $0.20 each under a prospectus, which will remains open until July 18 unless closed earlier. The company’s first anti-cancer drug candidate, NOX66, is poised to enter a phase I study later this year. It is a new dosage form of the drug candidate, idronoxil.
Regenerx Biopharmaceuticals Inc., of Rockville, Md., said it has entered a definitive agreement to sell 5.14 million shares of common stock at $0.34 each to a dedicated health care institutional investor in a private placement. The investor will also receive warrants to purchase up to 5.14 million shares of common stock with an exercise price of $0.51 per share and a five and one-half year term. Maxim Group LLC is acting as the sole placement agent for the offering.